GB Capital Subscribe
Market Fieldnotes1 minFreeGBC Research

Price-to-earnings ratio (P/E): calculation and limits

Price-to-earnings ratio (P/E): calculation and limits — Golden Bear Capital research

The price-to-earnings ratio divides share price by earnings per share. A hypothetical share priced at $40 with annual EPS of $2 has a P/E of 20. It is a description of the inputs, rather than a verdict on whether the share is attractive.

If expected EPS is $4, the same $40 price gives a forward P/E of 10. The forecast is doing the work. If actual EPS reaches only $1, the ratio based on that result is 40.

Trailing earnings describe a past period. Forward earnings depend on estimates and their chosen horizon. Check whether figures are reported or adjusted, and whether they refer to the same currency and share class.

Why comparisons need context

A cyclical company can look inexpensive when earnings are temporarily high. A one-off gain can inflate the denominator. If earnings are negative, a conventional positive P/E comparison is not available.

Debt, reinvestment needs and the durability of profits differ across companies. Two businesses with the same P/E can have different obligations and exposure to a downturn.

Keep the assumptions visible in your valuation work. Write which earnings period you used, the source of any estimate and what happens if the estimate changes.

For a small exercise, calculate ratios at $1, $2 and $4 EPS while holding the price at $40. Then identify what operational evidence would support each earnings case.

A $40 share price, three earnings assumptions
Annual EPSP/E
$140
$220
$410

Sources and further reading

Related research
Earnings per share (EPS): share count and dilution explainedMarket Fieldnotes · 05.10.2026Company debt: read the repayment calendarMarket Fieldnotes · 05.10.2026Equity X-Ray: In-Depth Research #32 · The $20 Billion Bet on the Chip That Should Not WorkEquity X-Ray · 09.09.2026Equity X-Ray: In-Depth Research #25 · The Printing Press for DNA: Fueling the Entire AI-Drug Discovery BoomEquity X-Ray · 21.10.2025GBC Playbook: Volume V · Your Trading Tech Stack: Professional Tools vs. Budget AlternativesPlaybook · 18.02.2026 Full archive →